Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 22/06/2010

    CureVac starts Phase IIa with mRNA immunotherapeutic in Non-Small Cell Lung Cancer

    CureVac GmbH, the mRNA company, today announced that the Paul-Ehrlich-Institute, the German regulatory authority for medicinal products, has approved the start of a Phase IIa trial for CV9201 to treat Non-Small Cell Lung Cancer (NSCLC).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-starts-phase-iia-with-mrna-immunotherapeutic-in-non-small-cell-lung-cancer
  • Dossier - 14/06/2010 11484_de.jpg

    Engineers of life

    Synthetic biology focuses on the development of biological systems with new defined characteristics assembled according to the principles of engineering. Synthetic biology has the potential to be used for a broad range of applications and has solutions in store for major problems of the future. It also fuels fears that human beings are playing the role of creators and going beyond natural boundaries.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/engineers-of-life
  • Press release - 02/06/2010

    immatics enters Collaboration with the National Cancer Institute (NCI)

    immatics biotechnologies GmbH announced on June 2nd, 2010 that it has signed a Clinical Trial Agreement with the Center for Cancer Research (CCR), National Cancer Institute (NCI), USA. The Agreement covers the clinical development of immatics’ therapeutic cancer vaccine IMA950 which is to be evaluated in the field of brain cancer, specifically glioblastoma, the most aggressive form of brain cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-enters-collaboration-with-the-national-cancer-institute-nci
  • Article - 24/05/2010 View into an opened chicken egg. A tumour, applied to the outer membrane, which is criss-crossed with numerous blood vessels, has grown in a spherical area.<br />

    Alternative CAM: chicken eggs to precede mouse experiments

    Researchers who test whether in vitro results can be transferred to living organisms prefer to use mice rats or rabbits. Many questions can be answered using the chorioallantoic membrane CAM of fertilised chicken eggs an alternative model to animal experiments that provides rapid results and only costs 50 cents per egg.

    https://www.gesundheitsindustrie-bw.de/en/article/news/alternative-cam-chicken-eggs-to-precede-mouse-experiments
  • Press release - 21/05/2010 11423_de.jpg

    The road to individualized tumour vaccines

    What are the typical cancer cell characteristics that our immune system is directed against? Using a new biochemical method, scientists from the Neurosurgery Department of the Heidelberg University Hospital and the German Cancer Research Centre (Deutsches Krebsforschungszentrum, DKFZ) are now able to answer this question for each individual patient. The method is expected to help identify new target structures for individualized tumour vaccines.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/the-road-to-individualized-tumour-vaccines
  • Press release - 12/05/2010 07777_de.jpg

    CureVac raises EUR 27.6 Million in Financing Round

    CureVac GmbH, the mRNA vaccine company, today announced the closing of a EUR 27.6 million (US$ 35.25 million) financing round with its major shareholder, dievini Hopp BioTech holding GmbH & Co. KG.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-raises-eur-27-6-million-in-financing-round
  • Article - 29/04/2010 VFA_4C.jpg

    The biopharmaceutical industry remained stable in times of crisis

    The German biopharmaceutical industry has come through 2009 without experiencing too many major slumps. The roaring growth of the biopharmaceutical industry in previous years has been replaced by more moderate growth. This is the result published by the 4th Medical Biotechnology report in 2010 compiled on behalf of the biotech interest group of the vfa bio Association of Research-Oriented Pharmaceutical Companies by the Boston Consulting Group.

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-biopharmaceutical-industry-remained-stable-in-times-of-crisis
  • Article - 19/04/2010 Scientist in the laboratory of Przybylski's reserach group at the University of Constance holding a test tube in her hand and standing in front of an analysis device.

    Natural antibodies to treat Alzheimer’s

    Alzheimers disease is characterised by changes in the substance and structure of the brain that are caused by the depositing of protein plaques in the brain. Prof. Michael Przybylski and his team of researchers at the University of Constance have deciphered the structure of the site where mouse antibodies attach to the plaques subsequently causing them to dissolve. These findings will now be used to identify the binding structure of a component…

    https://www.gesundheitsindustrie-bw.de/en/article/news/natural-antibodies-to-treat-alzheimer-s
  • Article - 26/03/2010 10970_de.jpg

    How do killer cells manage to survive?

    It is not easy for the body to protect itself once a virus has broken through the body’s lines of defence and caused a chronic infection. This task is made even more difficult when the intruders are viral hepatitis pathogens that attack the liver, the place where immunological tolerance is induced. Jörg Reimann (physician) and Reinhold Schirmbeck (biologist) are working on the development of T-cell-mediated therapeutic vaccination strategies to…

    https://www.gesundheitsindustrie-bw.de/en/article/news/how-do-killer-cells-manage-to-survive
  • Article - 18/03/2010 The photo shows a Y-shaped molecule. The major branch is shown in red and the other two in yellow.<br />

    Cancer treatment adapted to individual patient requirements

    There is still no treatment available for a number of non-Hodgkin B-cell lymphomas. Chemotherapy, which is the standard method of treating the lymphomas, has unpleasant side effects. Researchers led by Prof. Dr. Hendrik Veelken at the Freiburg University Medical Centre in cooperation with Freiburg-based CellGenix Technologie Transfer GmbH have developed a promising new treatment strategy. Results of the Phase I and the Phase II study, which has…

    https://www.gesundheitsindustrie-bw.de/en/article/news/cancer-treatment-adapted-to-individual-patient-requirements
  • Dossier - 15/03/2010 09298_de.jpg

    Vaccine development

    As the recent discussion on the pros and cons of swine flu vaccinations has shown vaccinations are not very popular in Germany. However people tend to forget that no other medical development has helped people to the same extent as immunisation with vaccines has done. Examples include the discovery of the cow pox vaccination by Edward Jenner in 1796 and all the programmes that have been set up by the Global Alliance for Vaccines and Immunisation…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/vaccine-development
  • Article - 15/03/2010 10701_de.jpg

    Campaign to eradicate malaria

    After many decades, efforts to develop an effective vaccine against malaria have finally brought researchers closer to their goal. However, the goal of eradicating malaria completely can only be reached through a complex strategy, to which researchers from Heidelberg are making intensive contributions.

    https://www.gesundheitsindustrie-bw.de/en/article/news/campaign-to-eradicate-malaria
  • Article - 15/03/2010 Human papillomaviruses - electron microscope photo

    The first active immunisations against cancer

    The first anti-cancer vaccines were developed to prevent women from becoming infected with papillomaviruses and to protect them against cervical cancer. The development of vaccines can be traced back to the work of Nobel Laureate Harald zur Hausen and his colleagues at the German Cancer Research Centre in Heidelberg. But more development is required in the field of anti-cancer vaccines and this is why researchers worldwide are working on vaccines…

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-first-active-immunisations-against-cancer
  • Article - 15/03/2010 10460_de.jpg

    Innovative navigation system enables gene shuttles to reach their destination

    If everything goes to plan the Department of Gene Therapy at the University of Ulm will soon lose a work group to industry. Florian Kreppels team plans to turn a particular technology into hard cash using a method that can do something other gene shuttles are unable to do namely transport their freight to a specific destination.

    https://www.gesundheitsindustrie-bw.de/en/article/news/innovative-navigation-system-enables-gene-shuttles-to-reach-their-destination
  • Article - 13/03/2010 10874_de.jpg

    Assembling life from building blocks?

    As part of its “Bioethics Forum”, the German Ethics Council recently held a meeting in Berlin to inform the public about the fundamentals of synthetic biology and potential ethical problems and consequences in terms of our ideas about life and mankind in general arising from the progress made in this new field of research.

    https://www.gesundheitsindustrie-bw.de/en/article/news/assembling-life-from-building-blocks
  • Dossier - 22/02/2010 10749_de.jpg

    Respiratory disease - congestion in the respiratory system

    Lung diseases are by far the most frequent cause of death worldwide. Every year three million people die from chronic obstructive pulmonary diseases 2.3 million die from lung cancer and 1.5 die from tuberculosis WHO World Health Organisation. There is no improvement in sight and experts believe that the number of deaths will continue to rise particularly in the case of chronic obstructive pulmonary diseases COPD lung cancer and tuberculosis TB.…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/respiratory-disease-congestion-in-the-respiratory-system
  • Press release - 04/02/2010 10640_de.jpg

    World Cancer Day: encouraging the prevention, detection and treatment of cancer

    World Cancer Day on the 4th of February is designed to raise awareness that cancer remains one of the major, often fatal human diseases. Every year, more than twelve million people worldwide develop cancer. The Helmholtz Association carries out research into the development of cancer and the underlying risk factors, and comes up with effective strategies for the prevention of cancer and for better diagnostics and targeted therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/world-cancer-day-encouraging-the-prevention-detection-and-treatment-of-cancer
  • Article - 15/12/2009 10453_de.jpg

    Arming the immune system against cancer

    The theory that immune cells are able to attack tumours has long been a theory with only a minority of supporters. However, this theory is currently experiencing a renaissance. In the future, it might even be possible to specifically alter T-lymphocytes in order to improve their ability to identify and destroy certain tumour types. Prof. Dr. Hanspeter Pircher and his team at the Freiburg University Medical Centre are focusing on the development…

    https://www.gesundheitsindustrie-bw.de/en/article/news/arming-the-immune-system-against-cancer
  • Press release - 08/12/2009 10296_de.jpg

    Vaccination of honeybees against the Varroa mite is possible

    For the first time ever, honeybees were orally ‚vaccinated’ with a genetically engineered product that was later detected in the bloodsucking Varroa mite. This product is a DNA-plasmid that is normally used for man, horses, swine and also for fish. The inventor of this innovative DNA-vaccination system for bees is Matthias Giese, PhD, who launches his own Institute for Molecular Vaccines (IMV) in Heidelberg/Germany starting in 2010.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/vaccination-of-honeybees-against-the-varroa-mite-is-possible
  • Article - 03/12/2009 10296_de.jpg

    Matthias Giese: DNA vaccine to combat worldwide honeybee deaths

    Varroa mites attach to the body of bees and weaken them by sucking hemolymph infecting them with viruses that are believed to be the cause of the mass death of European honeybee colonies. Matthias Giese of the Heidelberg-based Institute for Molecular Vaccines developed a DNA vaccine that might just lead to a breakthrough in the quest to get rid of the Varroa parasites. Giese tells us about his project in the following interview.

    https://www.gesundheitsindustrie-bw.de/en/article/news/matthias-giese-dna-vaccine-to-combat-worldwide-honeybee-deaths
  • Article - 14/11/2009 10116_de.jpg

    "A little naivety always helps"

    The biotech company CureVac based in Tuebingen is working on the development of a new tumour therapy based on RNA molecules. Dr. Ingmar Hoerr one of the scientists who founded CureVac tells Christoph Bächtle about the obstacles the young company had to overcome and the tough decisions that led to success. At the very start he tells us the company owes its origins to a huge dollop of luck.

    https://www.gesundheitsindustrie-bw.de/en/article/news/a-little-naivety-always-helps
  • Press release - 04/11/2009

    CureVac launches Phase IIa mRNA Vaccine Trial in Prostate Cancer

    CureVac GmbH, the mRNA vaccine company, today announced that the German authorities approved the start of the Phase IIa trial in Prostate Cancer after assessment of the first safety data of lead candidate CV9103, a RNActive®-derived mRNA vaccine. Results so far from the Phase I show CV9103 to be safe and well tolerated.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-launches-phase-iia-mrna-vaccine-trial-in-prostate-cancer
  • Press release - 12/10/2009

    Immatics appoints Carsten Reinhardt as Chief Medical Officer

    The biopharmaceutical company immatics biotechnologies GmbH announced the appointment of Dr Carsten Reinhardt as Chief Medical Officer (CMO) effective October 1, 2009. “I am very pleased to be joining immatics at this exciting stage of the company’s development” said Dr Reinhardt.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-appoints-carsten-reinhardt-as-chief-medical-officer
  • Press release - 12/10/2009

    Cancer Cells Suppress the Body’s Own Defense Mechanisms

    Cancer cells use tricks to evade the immune system. Thus, for example, they attract specific blood cells which suppress the body’s own defense mechanisms. Scientists of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), collaborating with colleagues of the University Surgical Hospital in Heidelberg and an international research team, have investigated these processes in bowel cancer. The results of their research have now…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cancer-cells-suppress-the-body-s-own-defense-mechanisms
  • Press release - 24/09/2009

    Call for innovative technologies that address global health concerns

    The World Health Organization is seeking innovative technologies, in particular medical devices that offer solutions to global health concerns in low- and middle-income countries. The deadline for submission of proposals is January the 31st 2010.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/call-for-innovative-technologies-that-address-global-health-concerns

Page 7 / 9

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2022
Website address: https://www.gesundheitsindustrie-bw.de/en/search